128043-60-7

Usage

Uses

Used in Organic Synthesis:
(3-BENZYL-2,4,5-TRIOXO-IMIDAZOLIDIN-1-YL)-ACETIC ACID ETHYL ESTER is used as a reagent in organic synthesis for its ability to facilitate various chemical reactions, contributing to the formation of new compounds with potential applications across different industries.
Used in Pharmaceutical Production:
In the pharmaceutical industry, (3-BENZYL-2,4,5-TRIOXO-IMIDAZOLIDIN-1-YL)-ACETIC ACID ETHYL ESTER is used as an intermediate in the development and manufacturing of drugs. Its unique structure allows it to be a building block for creating new medicinal compounds that can target specific biological pathways.
Used in Agrochemical Production:
(3-BENZYL-2,4,5-TRIOXO-IMIDAZOLIDIN-1-YL)-ACETIC ACID ETHYL ESTER is also utilized as an intermediate in the production of agrochemicals, where it can contribute to the development of new pesticides, herbicides, or other agricultural products designed to improve crop yields and protect against pests.
Used in Medicinal Chemistry Research:
(3-BENZYL-2,4,5-TRIOXO-IMIDAZOLIDIN-1-YL)-ACETIC ACID ETHYL ESTER is used in medicinal chemistry for research purposes, particularly in the development of new drugs. Its complex structure makes it a promising candidate for creating molecules that can interact with biological targets, potentially leading to the discovery of novel therapeutic agents.
Used in Specialty Chemicals and Advanced Materials Production:
(3-BENZYL-2,4,5-TRIOXO-IMIDAZOLIDIN-1-YL)-ACETIC ACID ETHYL ESTER may also find use in the production of specialty chemicals and advanced materials, where its unique properties can be leveraged to create new products with specific characteristics for various applications.

Upstream product

• 30345-85-8 1-benzyl-imidazolidine-2,4,5-trione 
• 105-36-2 ethyl bromoacetate 
• 100-46-9 benzylamine 
• 538-32-9 benzylurea 
• 3287-99-8 benzylamine hydrochloride 

Relevant academic research and scientific papers

Structure-activity relationship of 2,4,5-trioxoimidazolidines as inhibitors of thymidine phosphorylase

Novel non-nucleobase-derived inhibitors of the angiogenic enzyme, thymidine phosphorylase, have been identified using molecular modelling, synthesis and biological evaluation. These inhibitors are 2,4,5-trioxoimidazolidines bearing N-(substituted)phenylalkyl groups, together with, in most cases, N′-(CH2)n-carboxylic acid, ester or amide side chains. The best compound from this series is 3-(2,4,5-trioxo-3-phenylethyl- imidazolodin-1-yl)propionamide, with an IC50 of 40 μM against Escherichia coli TP. Molecular modelling suggests that this ligand, when complexed with closed-cleft human TP, would have the phenylalkyl group in the active site region normally occupied by a thymine-containing structure.

Highly selective aldose reductase inhibitors. 1. 3-(Arylalkyl)-2,4,5- trioxoimidazolidine-1-acetic acids

A series of 3-(arylalkyl)-2,4,5-trioxoimidazolidine-1-acetic acids (1) was prepared and tested for aldose reductase (AR) and aldehyde reductase (ALR) inhibitory activities. These compounds showed strong inhibitory activity against AR without significant inhibitory activity for ALR. The ratio of IC50(ALR)IC50(AR) was > 1000 in some compounds. On the basis of pharmacological tests such as the recovery of reduced motor nerve conduction velocity and toxicological profile, 3-(3-nitrobenzyl)-2,4,5- trioxoimidazolidine-1-acetic acid (NZ-314) was selected as the candidate for clinical development.

PARABANIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF

Parabanic acid compound of the formula (I): wherein R is hydrogen or a lower alkyl group, X is hydrogen, an alkyl group, a cycloalkyl group, a lower alkylcycloalkyl group, a phenyl group or a phenalkyl group, and n represents an integer of 1 to 4, exhibit